Study guide

38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes

Philippine Physician Licensure Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: PLE Structure, Eligibility & Study Strategy

1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan

2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle

2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction

3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems

3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments

4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems

4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation

5 Chapter 5: Physiology IV: Neurophysiology & Special Senses

5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses

6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death

6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death

7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning

7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws

8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics

8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics

9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics

9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock

10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection

10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology

11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology

11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura

12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology

12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors

13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry

13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism

14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry

14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure

15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back

15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes

16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin

16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands

17 Chapter 17: Anatomy III: Head, Neck & Histology

17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology

18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections

18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis

19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections

19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning

20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections

20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases

21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections

21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis

22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding

22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage

23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems

23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception

24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception

24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria

25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues

25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents

26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections

26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections

27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders

27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning

28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders

28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child

29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider

29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036

30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine

30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine

31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer

31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health

32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics

32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections

33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics

33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy

34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics

34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis

35 Chapter 35: Surgery I: Basic Surgical Principles

35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety

36 Chapter 36: Surgery II: Abdomen, Breast & Hernia

36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma

37 Chapter 37: Surgery III: Surgical Specialties

37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)

38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine

38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome

39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine

39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS

40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry

40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)

38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes

Key Takeaways Explain This Topic AI

Hypertension is diagnosed from repeated readings of 140/90 mmHg or more (or 130/80 by ACC/AHA); look for secondary causes in young patients, resistant hypertension, hypokalemia or a sudden rise.

STEMI needs reperfusion within 12 hours of onset: primary PCI within 120 minutes of first medical contact, otherwise fibrinolysis within 30 minutes of arrival.

A new loud holosystolic murmur 3 to 5 days after MI suggests papillary muscle rupture or ventricular septal rupture; sudden tamponade suggests free wall rupture.

HFrEF (EF 40% or less) is treated with four drug classes that lower mortality: ARNI or ACE inhibitor or ARB, an evidence-based beta-blocker, an MRA and an SGLT2 inhibitor.

Septic shock is sepsis needing vasopressors to keep MAP at 65 mmHg or more with lactate above 2 mmol/L despite fluids; give antibiotics within 1 hour and norepinephrine first-line.

Last updated: October 2026

Why this area matters

Heart disease is the leading cause of death in the Philippines , and hypertension is the most common chronic condition seen in primary care. The PLE asks you to recognize ACS on an ECG, choose reperfusion, start guideline-directed therapy for heart failure and resuscitate shock. Drug details are in the cardiovascular pharmacology sections; this section focuses on diagnosis and clinical decisions.

Hypertension

Diagnosis:

use repeated, properly measured office readings (seated, correct cuff size, two readings) confirmed by home or ambulatory BP monitoring where possible;

hypertension is 140/90 mmHg or more by Philippine, ESH and WHO thresholds; the ACC/AHA 2017 threshold is 130/80 mmHg;

white-coat hypertension is high in the clinic but normal at home; masked hypertension is the reverse.

Evaluation:

target-organ damage : left ventricular hypertrophy (ECG, echo), retinopathy, albuminuria and reduced eGFR, and prior stroke or CAD;

baseline tests: creatinine and eGFR, electrolytes, fasting glucose or HbA1c, lipids, urinalysis with albumin-to-creatinine ratio, and ECG;

total cardiovascular risk guides treatment intensity.

Treatment:

  • lifestyle : salt below 5 g a day, weight loss, the DASH diet, exercise, limiting alcohol and stopping smoking;
  • drugs for stage 2 hypertension , or for stage 1 with high risk or organ damage;
  • most patients need two drugs , ideally in a single pill;

targets below 130/80 mmHg for most patients who tolerate them.

Secondary hypertension: suspect it with onset before 30 years, resistant hypertension (uncontrolled on three drugs including a diuretic), sudden worsening, or suggestive features:

primary aldosteronism : hypertension with hypokalemia (often normal potassium); screen with the aldosterone-renin ratio;

renal artery stenosis : atherosclerotic in older smokers, fibromuscular dysplasia in young women; abdominal bruit, flash pulmonary edema, or creatinine rising more than 30% after an ACE inhibitor;

  • chronic kidney disease and glomerulonephritis;
  • pheochromocytoma : paroxysms of headache, sweating and palpitations;
  • Cushing syndrome , hyperthyroidism and obstructive sleep apnea (snoring, obesity, daytime sleepiness);
  • coarctation of the aorta : arm-leg BP difference and radiofemoral delay;

drugs : NSAIDs, oral contraceptives, steroids, decongestants and stimulants.

Hypertensive emergency (severe hypertension with acute organ damage) needs IV drugs and controlled lowering. Urgency without organ damage is managed with oral drugs.

Dyslipidemia and cardiovascular risk

Screening with a lipid profile in adults, earlier with diabetes, family history or other risk factors.

Secondary causes: diabetes, hypothyroidism , nephrotic syndrome, cholestasis, alcohol and drugs (steroids, thiazides, antiretrovirals).

Familial hypercholesterolemia: LDL of 190 mg/dL or more, tendon xanthomas , corneal arcus before 45, and premature CAD in the family.

LDL targets by risk (ESC/EAS 2019):

very high risk (established ASCVD, diabetes with organ damage, severe CKD): LDL below 55 mg/dL and a 50% reduction;

high risk : below 70 mg/dL;

moderate risk : below 100 mg/dL.

Treatment: lifestyle and statins first; add ezetimibe , then a PCSK9 inhibitor if targets are not met.

Triglycerides above about 500 mg/dL (especially above 1,000) risk acute pancreatitis : treat with fibrates, diet, alcohol avoidance and glucose control.

Stable coronary artery disease

Typical angina: constricting chest discomfort brought on by exertion or stress and relieved within minutes by rest or nitroglycerin.

Tests:

resting ECG and echo;

coronary CT angiography or stress testing (exercise ECG, stress echo or perfusion scan) depending on likelihood;

invasive angiography for high-risk findings or refractory symptoms.

Treatment:

  • aspirin (or clopidogrel) and a high-intensity statin for all;
  • beta-blockers or calcium channel blockers for symptoms, with sublingual nitroglycerin;
  • control of BP, diabetes and smoking;

revascularization (PCI or CABG) for refractory angina or high-risk anatomy (left main, three-vessel disease with diabetes or reduced EF).

Acute Coronary Syndromes (ACS)

Acute coronary syndromes encompass a spectrum of myocardial ischemia triggered by atherosclerotic plaque disruption, platelet activation, and coronary arterial thrombosis. ACS is categorized into ST-Elevation Myocardial Infarction (STEMI), Non-ST-Elevation Myocardial Infarction (NSTEMI), and Unstable Angina (UA) based on electrocardiographic (ECG) patterns and serum cardiac biomarkers.

Spectrum and Pathophysiology

STEMI: Represents acute, transmural myocardial ischemia caused by complete thrombotic occlusion of an epicardial coronary artery. It presents with persistent chest discomfort and new ST-segment elevations (or new left bundle branch block with concordant ST changes) and elevated cardiac biomarkers.

NSTEMI: Results from non-occlusive, subtotal thrombosis or dynamic vasospasm causing subendocardial necrosis. ECG reveals ST-segment depressions, T-wave inversions, or transient non-specific changes with elevated cardiac troponins.

Unstable Angina (UA): Characterized by myocardial ischemia without detectable myocyte necrosis (normal troponin levels). Symptoms occur at rest, represent new-onset severe angina, or demonstrate a crescendo pattern.

ECG Localization and Culprit Vessels

Electrocardiographic ST elevation in contiguous leads localizes the ischemic territory and identifies the culprit coronary artery:

Myocardial Territory Contiguous ECG Leads Culprit Coronary Artery Clinical Pitfalls & Associations

Septal V 1 , V 2 V_1, V_2 V 1 ​ , V 2 ​ Left Anterior Descending (LAD) Bundle branch blocks, ventricular septal rupture

Anterior V 3 , V 4 V_3, V_4 V 3 ​ , V 4 ​ Left Anterior Descending (LAD) High risk of anterior wall failure, apical aneurysm

Anteroseptal / Anterolateral V 1 − V 4 V_1 - V_4 V 1 ​ − V 4 ​ or V 1 − V 6 V_1 - V_6 V 1 ​ − V 6 ​ , I, aVL Proximal LAD / Left Main Coronary Cardiogenic shock, severe left ventricular dysfunction

Lateral I, aVL, V 5 , V 6 V_5, V_6 V 5 ​ , V 6 ​ Left Circumflex (LCx) or Diagonal of LAD Reciprocal depressions in inferior leads

Inferior II, III, aVF Right Coronary Artery (RCA) in 85-90%; LCx in 10-15% Bradycardia, high-degree AV block, papillary muscle rupture

Right Ventricular (RV) V 3 R , V 4 R V_3R, V_4R V 3 ​ R , V 4 ​ R (Right-sided ECG) Proximal Right Coronary Artery (RCA) Preload-dependent hypotension; nitrates are contraindicated

Posterior V 7 − V 9 V_7 - V_9 V 7 ​ − V 9 ​ (ST depression in V 1 − V 3 V_1 - V_3 V 1 ​ − V 3 ​ with tall R waves) Posterior Descending Artery (PDA from RCA or LCx) Easily missed on standard 12-lead ECG; obtain posterior leads

Biomarker Kinetics

High-Sensitivity Cardiac Troponin (hs-cTnI and hs-cTnT): Preferred diagnostic biomarkers due to near-absolute myocardial tissue specificity. Troponins rise within 2 to 4 hours of onset, peak at 24 to 48 hours, and remain elevated for 10 to 14 days.

CK-MB: Rises within 4 to 6 hours, peaks at 18 to 24 hours, and returns to baseline within 48 to 72 hours. It is clinically valuable for detecting early recurrent infarction (reinfarction) during the subacute phase.

Reperfusion Strategies and Emergency Pharmacotherapy

Time to myocardial reperfusion directly dictates myocardial salvage and survival:

Primary Percutaneous Coronary Intervention (PCI): The gold standard for acute STEMI. Primary PCI is recommended when the procedure can be performed within a door-to-balloon time of ≤ 90 minutes \le 90\text{ minutes} ≤ 90 minutes at a PCI-capable hospital, or within ≤ 120 minutes \le 120\text{ minutes} ≤ 120 minutes of first medical contact if inter-hospital transfer is required.

Fibrinolytic Therapy: Indicated for acute STEMI presenting within 12 hours of symptom onset when anticipated primary PCI-related delay exceeds 120 minutes. The target door-to-needle time is ≤ 30 minutes \le 30\text{ minutes} ≤ 30 minutes using fibrin-specific agents (tenecteplase, alteplase, or reteplase). Absolute contraindications include prior intracranial hemorrhage, known cerebrovascular structural lesion, ischemic stroke within 3 months (except within 4.5 hours), active internal bleeding, or suspected aortic dissection.

Adjunctive Medical Regimen:

Dual Antiplatelet Therapy (DAPT): Aspirin ( 162 to 325 mg 162\text{ to }325\text{ mg} 162 to 325 mg loading dose, followed by 81 mg 81\text{ mg} 81 mg daily indefinitely) plus a potent oral P 2 Y 12 P2Y_{12} P 2 Y 12 ​ inhibitor (Ticagrelor 180 mg 180\text{ mg} 180 mg load or Prasugrel 60 mg 60\text{ mg} 60 mg load; Clopidogrel 600 mg 600\text{ mg} 600 mg load before primary PCI when potent agents cannot be used; with fibrinolysis, Clopidogrel 300 mg 300\text{ mg} 300 mg load, or 75 mg 75\text{ mg} 75 mg without a load in patients older than 75 years).

Anticoagulation: Intravenous unfractionated heparin (UFH), enoxaparin, or bivalirudin.

Anti-ischemic Therapy: Sublingual or intravenous nitroglycerin (avoid if systolic blood pressure < 90 mmHg < 90\text{ mmHg} < 90 mmHg , heart rate < 50 bpm < 50\text{ bpm} < 50 bpm or > 100 bpm > 100\text{ bpm} > 100 bpm , right ventricular infarction, or recent phosphodiesterase-5 inhibitor use). Oral beta-blockers (metoprolol tartrate or carvedilol) should be initiated within 24 hours in hemodynamically stable patients without signs of acute heart failure or cardiogenic shock.

High-Intensity Statin Therapy: Atorvastatin 80 mg 80\text{ mg} 80 mg or Rosuvastatin 40 mg 40\text{ mg} 40 mg daily started immediately regardless of baseline lipid levels.

Complications after myocardial infarction

Timing Complication Clues

First 24 to 48 hours Arrhythmias (VF, VT, AV block) The main cause of early death; AV block common with inferior MI

Early, with inferior MI Right ventricular infarction Hypotension, raised JVP and clear lungs ; give fluids, avoid nitrates

Days 3 to 5 Papillary muscle rupture Acute MR, pulmonary edema and a new apical murmur

Days 3 to 5 Ventricular septal rupture New harsh holosystolic murmur at the left sternal border and an oxygen step-up in the right ventricle

  • Days 5 to 14 Free wall rupture Sudden tamponade and pulseless electrical activity
  • Weeks Left ventricular aneurysm Persistent ST elevation , heart failure, thrombus and VT
  • Weeks Dressler syndrome Autoimmune pericarditis with fever and a rub

Cardiogenic shock after MI is treated with urgent revascularization , inotropes and vasopressors, and mechanical support.

Secondary prevention after MI: aspirin plus a P2Y12 inhibitor for 12 months, high-intensity statin, beta-blocker, ACE inhibitor (especially with reduced EF), cardiac rehabilitation and stopping smoking.

Heart failure

Common causes in the Philippines: hypertension, ischemic heart disease, rheumatic valve disease , cardiomyopathies (dilated, including alcoholic and peripartum) and thyroid disease.

Clinical diagnosis: dyspnea, orthopnea , paroxysmal nocturnal dyspnea , fatigue, edema, raised JVP, an S3 , crackles and hepatomegaly (the Framingham criteria combine these).

Tests:

  • natriuretic peptides : BNP below 100 pg/mL or NT-proBNP below 300 pg/mL makes acute HF unlikely;
  • echocardiography gives the EF and the cause;

chest X-ray shows cardiomegaly, upper-lobe diversion, Kerley B lines and effusions.

Precipitants of decompensation: non-adherence to drugs or salt restriction, ischemia, arrhythmias (especially atrial fibrillation), infection, uncontrolled hypertension, NSAIDs, anemia, thyroid disease and pregnancy.

Heart Failure (HF): Chronic GDMT & Acute Hemodynamics

Heart failure is a complex clinical syndrome resulting from structural or functional ventricular impairment, categorized by left ventricular ejection fraction (LVEF):

HFrEF (Reduced Ejection Fraction): LVEF ≤ 40 % \text{LVEF} \le 40\% LVEF ≤ 40% .

HFmrEF (Mildly Reduced Ejection Fraction): LVEF 41 − 49 % \text{LVEF } 41-49\% LVEF 41 − 49% .

HFpEF (Preserved Ejection Fraction): LVEF ≥ 50 % \text{LVEF} \ge 50\% LVEF ≥ 50% .

NYHA Functional Classification

Class I: Cardiac disease without resulting limitation of ordinary physical activity.

Class II: Slight limitation; comfortable at rest, but ordinary physical activity causes fatigue, palpitations, or dyspnea.

Class III: Marked limitation; comfortable at rest, but less than ordinary activity causes fatigue or dyspnea.

Class IV: Inability to carry on any physical activity without discomfort; symptoms present at rest.

The Four Pillars of Guideline-Directed Medical Therapy (GDMT) for HFrEF

In all patients with symptomatic HFrEF, four pharmacologic drug classes provide additive mortality reduction and must be titrated to maximum tolerated target doses:

Angiotensin Receptor-Neprilysin Inhibitor (ARNI): Sacubitril/valsartan is preferred over ACE inhibitors or ARBs. Sacubitril inhibits neprilysin (preventing breakdown of endogenous natriuretic peptides, bradykinin, and adrenomedullin), while valsartan blocks angiotensin II type 1 receptors. If switching from an ACE inhibitor to an ARNI, a mandatory 36-hour washout period is required to prevent life-threatening angioedema.

Evidence-Based Beta-Blockers: Specifically Carvedilol , Metoprolol Succinate (extended-release), or Bisoprolol . Beta-blockers must be initiated when the patient is euvolemic and hemodynamically stable, beginning at low doses and uptitrated every 2 to 4 weeks.

Mineralocorticoid Receptor Antagonists (MRAs): Spironolactone or eplerenone, indicated for NYHA Class II-IV with LVEF ≤ 35 % \text{LVEF} \le 35\% LVEF ≤ 35% , provided serum potassium is < 5.0 mEq/L < 5.0\text{ mEq/L} < 5.0 mEq/L and estimated GFR is > 30 mL/min/1.73 m 2 > 30\text{ mL/min/1.73 m}^2 > 30 mL/min/1.73 m 2 .

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Dapagliflozin ( 10 mg 10\text{ mg} 10 mg daily) or Empagliflozin ( 10 mg 10\text{ mg} 10 mg daily) reduce cardiovascular death and heart failure hospitalizations regardless of diabetes status.

Symptom Management: Loop diuretics (furosemide, bumetanide, torsemide) relieve pulmonary and peripheral congestion but do not confer independent survival benefits.

Acute Decompensated Heart Failure (ADHF): Forrester Hemodynamic Subsets

Acute heart failure decompensation is stratified based on clinical perfusion ("warm" versus "cold", cardiac index cutoff 2.2 L/min/m 2 2.2\text{ L/min/m}^2 2.2 L/min/m 2 ) and pulmonary congestion ("dry" versus "wet", pulmonary capillary wedge pressure cutoff 18 mmHg 18\text{ mmHg} 18 mmHg ):

Forrester Subset Perfusion (CI) Congestion (PCWP) Clinical Presentation Immediate Therapeutic Strategy

Subset I (Warm & Dry) Normal ( ≥ 2.2 \ge 2.2 ≥ 2.2 ) Normal ( ≤ 18 \le 18 ≤ 18 ) Compensated; warm extremities, clear lungs Optimize chronic oral GDMT; observe

Subset II (Warm & Wet) Normal ( ≥ 2.2 \ge 2.2 ≥ 2.2 ) Elevated ( > 18 > 18 > 18 ) Adequate perfusion with pulmonary edema, orthopnea, elevated JVP Intravenous loop diuretics + intravenous vasodilators (nitroglycerin or nitroprusside)

Subset III (Cold & Dry) Depressed ( < 2.2 < 2.2 < 2.2 ) Normal ( ≤ 18 \le 18 ≤ 18 ) Cool extremities, prerenal azotemia, oliguria, no congestion Gentle, cautious intravenous fluid challenge if hypovolemic; hold high-dose vasodilators

Subset IV (Cold & Wet) Depressed ( < 2.2 < 2.2 < 2.2 ) Elevated ( > 18 > 18 > 18 ) Cardiogenic shock: profound hypotension, pulmonary congestion, cool clammy skin Intravenous inotropes (dobutamine or milrinone), vasopressors (norepinephrine), mechanical circulatory support (IABP, Impella)

More on heart failure:

HFpEF is treated with diuretics for congestion, an SGLT2 inhibitor , and control of BP, AF and comorbidities.

Devices:

an ICD for EF of 35% or less with NYHA class II to III despite at least 3 months of therapy;

cardiac resynchronization therapy for EF of 35% or less with LBBB and QRS 150 ms or more .

Self-care: daily weights, salt restriction, fluid limits in severe HF, vaccination and exercise training.

Shock syndromes

  • Type Examples Cardiac output SVR Filling pressure (JVP, PCWP)
  • Hypovolemic Hemorrhage, dengue plasma leakage, diarrhea Low High Low
  • Cardiogenic MI, myocarditis, acute valve failure Low High High
  • Distributive Sepsis , anaphylaxis, neurogenic, adrenal crisis Usually high (early sepsis) Low Low or normal
  • Obstructive Tension pneumothorax , tamponade , massive PE Low High High (JVP)

Sepsis (Sepsis-3): life-threatening organ dysfunction from a dysregulated response to infection, with an acute rise in the SOFA score of 2 or more . qSOFA (RR 22 or more, altered mentation, systolic BP 100 or less) flags risk but is not used alone for screening.

Septic shock: sepsis needing vasopressors to keep MAP at 65 mmHg or more with lactate above 2 mmol/L despite adequate fluids.

Surviving Sepsis Campaign 2021 first-hour management:

  • blood cultures , then broad-spectrum antibiotics within 1 hour for possible septic shock or probable sepsis;
  • measure lactate and repeat it if raised;

30 mL/kg of crystalloid (balanced solutions preferred) within the first 3 hours for hypotension or lactate of 4 mmol/L or more;

norepinephrine first-line to keep MAP at 65 mmHg or more , adding vasopressin and then hydrocortisone if needed;

source control (drain abscesses, remove infected lines).

Anaphylaxis: IM epinephrine 0.5 mg (0.01 mg/kg) into the anterolateral thigh, repeated every 5 to 15 minutes, with fluids, oxygen, then antihistamines and steroids as adjuncts.

Cardiogenic shock: treat the cause (revascularize an MI), give inotropes such as dobutamine with norepinephrine for hypotension, and use mechanical support in selected patients.

Loading diagram... Clinical Triage and Reperfusion Strategy in Acute ST-Elevation Myocardial Infarction